The median effective dose of oxycellidine combined with ciprofol to inhibit the body movement response during painless artificial abortion

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500100406

Enrollment

Unknown

Registered

2025-04-09

Start date

2024-11-24

Completion date

Unknown

Last updated

2025-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

painless artificial abortion

Interventions

Group A:Ocelidine was slowly injected intravenously according to the modified sequential method, and ciprofol 0.4 mg/kg was slowly injected intravenously over

Eligibility

Sex/Gender

Female

Age

18 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1.Patients undergoing painless artificial abortion were aged 18 to 35 years, BMI 18 to 28 kg/m^2, ASA I or II, fetal age < 10 weeks, first pregnancy or no history of vaginal delivery.

Exclusion criteria

Exclusion criteria: 1.Severe organ dysfunction; 2.history of drug abuse; 3.cognitive impairment; 4.allergy to related drugs or ingredients; 5.participation in other drug clinical trials in the past 3 months.

Design outcomes

Primary

Measure	Time frame
Movement response;ED50;	—

Countries

China

Contacts

Public ContactXU Hai

the Second Hospital of Jiaxing

xhjxey@163.com+86 573 82080930

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026